Roberts, Stephanie A.
Dougan, Michael
Article History
First Online: 25 August 2022
Competing interests
: M.D. has research funding from Novartis and Eli Lilly and Company; has received consulting fees from Tillotts Pharma, ORIC Pharmaceuticals, Partner Therapeutics, SQZ Biotech, AzurRx, Eli Lilly and Company, Mallinckrodt Pharmaceuticals, Aditum and Moderna; and is a member of the scientific advisory board for Neoleukin Therapeutics. S.A.R. declares no competing interests.